Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

Small molecule inhibitors of PARP1/2 such as olaparib have been proposed to serve as a synthetic lethal therapy for cancers that harbor BRCA1 or BRCA2 mutations. Indeed, in clinical trials PARP1/2 inhibitors elicit sustained anti-tumor responses in patients with germ-line BRCA gene mutations. In hyp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Bajrami, Ilirjana, Frankum, Jessica R., Konde, Asha, Miller, Rowan E., Rehman, Farah L., Brough, Rachel, Campbell, James, Sims, David, Rafiq, Rumana, Hooper, Sean, Chen, Lina, Kozarewa, Iwanka, Assiotis, Ioannis, Fenwick, Kerry, Natrajan, Rachael, Lord, Christopher J., Ashworth, Alan
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4886090/
https://ncbi.nlm.nih.gov/pubmed/24240700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-2541
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados